ReproCELL Incorporated (4978) Cash flow
Market cap
¥12.1B
P/E ratio
-25.5x
Reprocell develops iPS cell technology for research and medical applications, providing lab products and services to pharmaceutical companies while advancing regenerative medicine treatments.
| 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Depreciation & amortization | 83 | 174 | 114 | 120 | 41 | 55 | 59 | 57 | 46 | 34 | 48 | 72 |
| Cash from operations | -627 | -614 | -775 | -637 | -555 | -690 | -649 | -246 | -141 | -11 | 6 | -384 |
| Capital expenditures | -32 | -29 | -66 | -43 | -92 | -120 | -60 | -43 | -150 | -171 | -87 | -98 |
| Cash from investing | -2,684 | -569 | 686 | -228 | -2,308 | 1,218 | -1,417 | -2,144 | -1,087 | 404 | -796 | 58 |
| Repurchases of common stock | - | - | - | - | - | - | - | -0 | - | - | - | - |
| Repayments of term debt | - | - | - | - | - | - | - | - | -80 | - | - | - |
| Cash from financing | 2,016 | 1,700 | 1,128 | 1,029 | 1,381 | 7 | 4 | 2,385 | 483 | 544 | 680 | - |